Akili's transition to a non-prescription business model means its products will be more readily available to consumers, potentially increasing its customer base. The pursuit of OTC labeling also indicates the company's intent to comply with regulatory standards, which could enhance its reputation and trustworthiness among consumers. Both these factors could potentially lead to increased sales, positively impacting the company's stock price in the short term.